Tag : BNT162b2

With up to 6 months of follow-up in an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, the 6-month safety and efficacy data of BNT162b2 mRNA COVID-19 have been updated and summarized in this report. The current outbreak of the novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discovered in January 2020, has spread to countries around the world with recent estimates of more than 200 million cases diagnosed and over 4 million deaths. Coronaviruses are enveloped, positive-sense single‐stranded ribonucleic acid (RNA) viruses, and SARS-CoV-2 belongs to the B lineage of the beta-coronaviruses. The predominant clinical manifestations of SARS-CoV-2 include fever, cough, and other symptoms and signs of respiratory tract infections.